Mrs Myrtle Naomi Rogers, RN BSN COLON HYDROTH | |
21 Golden Grove, Frederiksted, VI 00840 | |
(340) 513-2343 | |
Not Available |
Full Name | Mrs Myrtle Naomi Rogers |
---|---|
Gender | Female |
Speciality | Naturopath |
Location | 21 Golden Grove, Frederiksted, Virgin Island |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205172376 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | 4898 (Virgin Island) | Secondary |
175F00000X | Naturopath | F-MR2125092 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Myrtle Naomi Rogers, RN BSN COLON HYDROTH Rr 1 Box 10008, Kingshill, VI 00850-9782 Ph: (340) 513-2343 | Mrs Myrtle Naomi Rogers, RN BSN COLON HYDROTH 21 Golden Grove, Frederiksted, VI 00840 Ph: (340) 513-2343 |
News Archive
Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.
ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today the publication of an important clinical trial demonstrating that patients treated with ArthroCare's Plasma Disc Decompression (PDD) products experienced reduced pain and better quality of life scores compared to patients treated with the current standard care, epidural steroid injections.
Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.
KYTHERA Biopharmaceuticals, Inc. today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness.
The loss of complete segments of the esophagus often results from treatments for esophageal cancer or congenital abnormalities, and current methods to re-establish continuity are inadequate.
› Verified 1 days ago